Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement and multi-year collaboration aimed at optimizing Biogen’s clinical development processes.
The collaboration will focus on clinical trial efficiency, transparency, quality, innovation and operational excellence. Quintiles will work with Biogen on the design, planning and execution of Biogen’s Phase II-IV studies and select Phase I studies. Biogen will also leverage Quintiles’ technology and systems.
“Our partnership with Biogen Idec exemplifies the ongoing evolution of drug development collaboration and reinforces the increasingly important role that biopharmaceutical service providers such as Quintiles have in these efforts,” said Tom Pike, chief executive officer, Quintiles. “We are extremely excited about this agreement and the increased interest we are seeing for these types of innovative development deals. We believe Quintiles is uniquely positioned to help our customers improve their probability of success through these collaborations, and we look forward to working closely with Biogen Idec.”
“As we have continued to build our research and development organization, it was important for us to identify a strong clinical development partner to complement our focus on developing innovative therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases,” said Alfred Sandrock, M.D., Ph.D., group senior vice president, Development Sciences and chief medical officer, Biogen Idec. “What attracted us to Quintiles was their depth and breadth of experience, which we believe will enhance the design, planning and operational elements of our clinical programs."